Quince Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Quince Therapeutics has a total shareholder equity of $85.1M and total debt of $13.4M, which brings its debt-to-equity ratio to 15.8%. Its total assets and total liabilities are $167.9M and $82.8M respectively.
Key information
15.8%
Debt to equity ratio
US$13.43m
Debt
Interest coverage ratio | n/a |
Cash | US$75.06m |
Equity | US$85.08m |
Total liabilities | US$82.82m |
Total assets | US$167.90m |
Recent financial health updates
Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation
Nov 21We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
Dec 15We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth
Aug 23We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
May 10Recent updates
Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation
Nov 21Cortexyme to change name and ticker symbol next month
Jul 27Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
Mar 01Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Dec 15We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
Dec 15Cortexyme: A Challenging Path Forward
Nov 17Cortexyme: Positive Lessons To Be Learned From Disappointing Results
Nov 01Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Oct 11Cortexyme: Alzheimer's Readout In November A Binary Event
Sep 12We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth
Aug 23Cortexyme EPS beats by $0.02
May 10We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
May 10Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares
Mar 10Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth
Feb 09Cortexyme: A Fresh Perspective In Alzheimer's
Jan 12Have Insiders Been Buying Cortexyme, Inc. (NASDAQ:CRTX) Shares This Year?
Dec 18Financial Position Analysis
Short Term Liabilities: QNCX's short term assets ($77.4M) exceed its short term liabilities ($9.6M).
Long Term Liabilities: QNCX's short term assets ($77.4M) exceed its long term liabilities ($73.2M).
Debt to Equity History and Analysis
Debt Level: QNCX has more cash than its total debt.
Reducing Debt: QNCX's debt to equity ratio has increased from 0% to 15.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QNCX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: QNCX has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 9% each year.